Exscientia (NASDAQ:EXAI) Stock Price Up 6.5%

Shares of Exscientia plc (NASDAQ:EXAI) were up 6.5% during mid-day trading on Wednesday . The company traded as high as $5.48 and last traded at $5.43. Approximately 147,576 shares were traded during trading, a decline of 77% from the average daily volume of 629,249 shares. The stock had previously closed at $5.10.

Analyst Ratings Changes

Separately, Morgan Stanley reissued an “equal weight” rating and set a $7.00 price objective on shares of Exscientia in a research report on Monday, April 22nd.

Exscientia Trading Up 5.3 %

The business’s fifty day moving average is $5.02 and its two-hundred day moving average is $5.64. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.05. The firm has a market cap of $649.16 million, a price-to-earnings ratio of -4.12 and a beta of 0.84.

Exscientia (NASDAQ:EXAI) last released its earnings results on Tuesday, May 21st. The company reported ($0.21) earnings per share for the quarter. The firm had revenue of $6.70 million for the quarter. Exscientia had a negative return on equity of 34.59% and a negative net margin of 666.80%. Equities analysts anticipate that Exscientia plc will post -1.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Banque Pictet & Cie SA bought a new position in shares of Exscientia during the third quarter worth $1,040,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Exscientia by 359.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock worth $34,000 after purchasing an additional 4,104 shares in the last quarter. Private Advisor Group LLC boosted its holdings in Exscientia by 114.3% during the fourth quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock worth $144,000 after purchasing an additional 12,000 shares during the last quarter. Raymond James Financial Services Advisors Inc. acquired a new position in Exscientia during the fourth quarter worth $207,000. Finally, Federated Hermes Inc. bought a new position in Exscientia in the third quarter valued at $362,000. Institutional investors and hedge funds own 41.58% of the company’s stock.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.